not vested
On the road to a healthier future
We see strong earnings from the healthcare division and increased online penetration for digital services driving MyEG’s net profit growth in FY21F.
Reiterate Add with an unchanged RM2.50 TP, based on a higher 26x P/E.
Potential tax incentive extension, implementation of e-testing services and Covid-19 vaccine commercialisation are key re-rating catalysts for the stock.
Source: CIMB
https://rfs.cgs-cimb.com/api/download?f ... EB68CE64B4